Health Care/Hospital Global News & Press Release Distribution

Health Care/Hospital

All
APAC

Welcome to 2024 Chinese Congress of Holistic Integrative Oncology (2024 CCHIO)& 4th International Congress of the Asian Oncology Society (AOS2024)

XI'AN, China, Nov. 9, 2024 /PRNewswire/ -- On behalf of the organizing committee of the 2024 Chinese Congress on Holistic Integrative Oncology (CCHIO), we are very pleased to invite you to attend the 2024 CCHIO & 4th International Congress of the Asian Oncology Society (AOS2024) . This esteemed ...

2024-11-09 14:45 3490

Mabwell Reveals Encouraging Pre-clinical Data of 7MW4811 at the 15th World ADC Conference

SHANGHAI, Nov. 8, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, showcased the "Preclinical Development of 7MW4811, an Mtoxin™ (MF6)-based Antibody-drug Conjugate for the Treatment of Solid Tumors" as a poster presentation at the 15 t...

2024-11-08 22:00 2330

Lunit Shows Promise of AI in Predicting Immunotherapy Response for Rare Cancer Patients at SITC 2024

Study reveals potential of AI-powered tumor microenvironment assessment in predicting treatment outcomes in rare cancer patients receiving pembrolizumab SEOUL, South Korea, Nov. 8, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and t...

2024-11-08 22:00 2568

Lunit Shows Promise of AI in Predicting Immunotherapy Response for Rare Cancer Patients at SITC 2024

Samsung Biologics earns ISO certifications in recognition of business excellence

* The company adds new ISO certification for compliance management and certified to updated standards for information and cloud security * Certifications recognize Samsung Biologics' commitment to operational excellence and demonstrates the company's reliability and integrity as a trusted CDM...

2024-11-08 20:00 1422

Dizal Submits New Drug Application to the U.S. FDA for Sunvozertinib in Treating Relapsed or Refractory Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

The submission is supported by data from the pivotal WU-KONG1 Part B study, which featured in an oral session at the 2024 ASCO Annual Meeting Sunvozertinib is the world's first and only oral drug approved for NSCLC patients with EGFR exon20ins SHANGHAI, Nov. 8, 2024 /PRNewswire/ -- Dizal (SSE:68...

2024-11-08 18:01 1178

Harbour BioMed Announces Submission of IND Application for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Nov. 8, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunolo...

2024-11-08 17:45 1090

Infinitopes to Showcase Breakthroughs on Cancer Vaccine Development at SITC 2024: Insight into a double-blind, Phase I/IIa clinical trial

* Infinitopes' lead vaccine candidate ITOP1 is a novel, precision targeted, immunologically durable, "off-the-shelf" cancer vaccine, designed to save lives by preventing disease recurrence in first-line patients with surgically resectable cancers * Infinitopes' proprietary vector delivery sys...

2024-11-08 16:30 1448

WuXi XDC Named Best CDMO Winner at 2024 World ADC Awards

SHANGHAI and SAN DIEGO, Nov. 7, 2024 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC" or the "Company", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in antibody-drug conjugates (ADCs) and other bioconjugates (XDCs), is ...

2024-11-08 11:27 1685

WuXi XDC Named Best CDMO Winner at 2024 World ADC Awards

InxMed Presents Data regarding Potential Novel Way to Improve Therapeutic Window of ADC by Ifebemtinib and FIC ADC at 15th Annual World ADC

NANJING, China, Nov. 7, 2024 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company developing innovative therapies against tumor-treatment resistance and metastasis, is presenting preclinical data at 15th Annual World ADC Conference in San Diego regarding ifebemtinib (ifebe, IN1...

2024-11-08 10:40 1324

Ping An Health and Medtronic Form Strategic Partnership at the China International Import Expo (CIIE)

HONG KONG and SHANGHAI, Nov. 7, 2024 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor", "Ping An Health", or "the Company", Stock Code: 1833.HK) established a strategic partnership with Medtronic (Shanghai) Management Co., Ltd. ("Medtronic") at the 7th China...

2024-11-08 10:04 1373

Ping An Health and Medtronic Form Strategic Partnership at the China International Import Expo (CIIE)

Shanghai thriving as global investment hub

BEIJING, Nov. 7, 2024 /PRNewswire/ -- A news report from chinadaily.com.cn： The 2024 Shanghai City Investment Promotion Conference, held on Nov 6, serves as a window for global businesses to exploreShanghai's evolving business environment and investment opportunities. The event, part of the 2024...

2024-11-08 09:34 1274

Shanghai thriving as global investment hub

Akeso Published Mechanism of Action for CLDN18.2/CD47 Bispecific Antibody AK132 for the First Time at SITC Annual Meeting

HONG KONG, Nov. 7, 2024 /PRNewswire/ -- At the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024), held inHouston, USA, from November 6 - 10, Akeso Biopharma (9926. HK) presented the mechanism of action (MOA) research findings of its innovative bispecific antibody, AK132, ...

2024-11-08 08:20 1325

What to see at the 7th China International Import Expo

SHANGHAI, Nov. 7, 2024 /PRNewswire/ -- A news report from english.shanghai.gov.cn Scan the QR code to learn more about the exhibition highlights of the 7th China International I...

2024-11-07 23:17 1707

What to see at the 7th China International Import Expo

United Imaging Receives First Approval in Canada

The uMI Panorama™ is being readied for sale in Canada and will ship from the company'sHouston-based North American headquarters. HOUSTON, Nov. 7, 2024 /PRNewswire/ -- United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, has received Health Canada approval for ...

2024-11-07 22:00 1097

CARsgen® to Present Zevor-cel, CT071 and CT0590 at ASH 2024 Annual Congress

SHANGHAI, Nov. 6, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the Company will present the clinical data of zevorcabtagene auto...

2024-11-06 21:50 1484

I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer

ROCKVILLE, Md., Nov. 6, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that Sean (Xi-Yong) Fu, PhD, MBA has been appointed ...

2024-11-06 20:00 993

MEGAROBO Unveils High-Content Cell Imaging System for Advanced Multidimensional Biological Analysis

BEIJING, Nov. 6, 2024 /PRNewswire/ -- MEGAROBO , a leading provider of advanced productivity tools for life sciences, has recently unveiled the CellVue™ T2000 high-content cell imaging system. The new cell imaging system is more than a digital microscope, featuring a hig...

2024-11-06 19:00 1358

Minghui Pharmaceutical Announces Promising Initial Results from Phase I Clinical Trial of MHB039A, a Novel PD-1 x VEGF Bispecific Antibody, in Patients with Relapsed/Refractory Solid Tumors

SHANGHAI, Nov. 6, 2024 /PRNewswire/ -- Minghui Pharmaceutical, Inc., a late-stage biopharmaceutical company focused on developing transformative medicines in immunology and oncology, today announced initial results from its Phase I clinical trial of MHB039A, a novel PD-1 x VEGF bispecific antibod...

2024-11-06 18:00 2941

Hanmi Unveils Novel Obesity Drug 'HM17321' : A Game-Changer in Overcoming GLP-1-Associated Muscle Loss

Fat Loss Augmentation + Lean Mass Increase Hanmi Presents Three Breakthrough Findings on Novel Obesity Drugs at 2024 ObesityWeek High Quality Obesity Management by Targeting the CRF2 Receptor: Enhanced Fat Loss with Lean Mass Increase Improved Weight Loss and Muscle Preservation with HM15275 Comb...

2024-11-06 15:41 1046

QureBio Ltd. to Present its Q-1802 Clinical PhaseⅡ Data at 2024 SITC 39th Annual Meeting

SHANGHAI, Nov. 6, 2024 /PRNewswire/ -- QureBio Ltd., a clinical-stage biopharmaceutical company focusing on development of bispecific antibodies and other engineered Biopharmaceuticals for the treatment of cancer, inflammation, and other serious disorders, today announced that Phase Ⅱ Clinical Da...

2024-11-06 13:00 1124

1 2 345 6 7 ... 277

Week's Top Stories

Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies

[Picked up by 283 media titles]

2024-11-20 09:00